Abstract

Background. Macrolides show high minimum inhibitory concentrations (MICs) against Pseudomonas aeruginosa when tested in recommended media (cation-adjusted Muller-Hinton broth [CA-MHB]). Nevertheless, azithromycin is successfully used in cystic fibrosis patients, supposedly because of “nonantibiotic effects.”

Methods. CA-MHB and Roswell Park Memorial Institute (RPMI) 1640 medium (used for growing eukaryotic cells) were compared for measuring azithromycin MICs (with or without Phe-Arg-β-naphthylamide [PAβN], an efflux inhibitor), [14C]-clarithromycin accumulation, azithromycin-induced protein synthesis inhibition, oprM (encoding the outer-membrane protein coupled with MexAB and MexXY efflux systems) expression, outer-membrane permeability (tested with 1-N-phenylnaphthylamine and nitrocefin), and synergy (determined by checkerboard assay) between azithromycin and outer-membrane disrupting agents. Key experiments were repeated with CA-MHB supplemented with serum, mouse bronchoalveolar lavage fluid, other macrolides, and other gram-negative bacteria.

Results. Azithromycin MICs were ≥128 mg/L in CA-MHB, compared with 1–16 mg/L in RPMI 1640 medium, CA-MHB supplemented with serum, or bronchoalveolar lavage fluid (repeated for RPMI 1640 medium with clarithromycin, other macrolides, and other gram-negative bacteria). [14C]-clarithromycin accumulation was 2.2-fold higher in RPMI 1640 medium, compared with CA-MHB. Inhibition of >95% of protein synthesis was obtained with azithromycin at 16 mg/L in RPMI 1640 medium, compared with >512 mg/L in CA-MHB. Strains not expressing oprM showed an MIC of 4 mg/L in CA-MHB. PAβN decreased MICs in CA-MHB but not in RPMI 1640 medium. Real-time polymerase chain reaction showed downregulation of oprM by azithromycin in RPMI 1640 medium. Outer-membrane permeability was 3–4.5 times higher in RPMI 1640 medium or bronchoalveolar lavage fluid, compared with CA-MHB. Azithromycin combined with outer-membrane disrupting agents were synergistic in CA-MHB but indifferent in RPMI 1640 medium.

Conclusions. Macrolides show antimicrobial activity against P. aeruginosa in eukaryotic media through increased uptake and reduced efflux. These data may help explain the clinical efficacy of macrolides against pseudomonal infections.

Pseudomonas aeruginosa is considered to be naturally resistant to several classes of antibiotics [1]; this is usually ascribed to low permeability [2], constitutive expression of efflux systems [3], and production of antibiotic-inactivating enzymes [4]. Thus, macrolide minimum inhibitory concentrations (MICs; measured as recommended by the Clinical Laboratory Standards Institute [5]) largely exceed serum and tissue concentrations reachable in humans. Yet, macrolides are widely used in the treatment of respiratory tract infections caused by P. aeruginosa, especially in cystic fibrosis patients, for whom clinical benefit has been clearly demonstrated [6, 7]. This is assumed to result from nonantibiotic effects, such as enhancement of host defenses [8], anti-inflammatory activities [9], inhibition of the expression of virulence factors or of quorum sensing [10], alteration of the bacterial outer membrane [11], and/or destruction of biofilms [12]. During a systematic survey of antibiotic activity in media used for culturing eukaryotic cells, we noted that the azithromycin MIC against P. aeruginosa was considerably lower in these media as compared to the recommended cation-adjusted Mueller-Hinton broth (CA-MHB; [5]). Since this observation could be extended to other macrolides and ketolides and other biological media of eukaryotic origin, we suspected that CA-MHB could actually modulate the physiology of P. aeruginosa, making it apparently resistant to macrolides if tested in that medium.

Our aim was to systematize these observations and to decipher their underlying mechanism(s). We show that the permeability of the outer membrane of P. aeruginosa is considerably lower in microbiological broths than in eukaryotic media and that bacteria exposed to azithromycin in CA-MHB express oprM (encoding a protein essential for active efflux of antibiotics) to a much larger extent in broth than in eukaryotic media. These mutually supportive effects are associated with an increased accumulation of macrolides, explaining why these antibiotics can exert true antibiotic effects in eukaryotic media at much lower concentrations than what has been generally assumed on the basis of conventional antibiotic susceptibility testing.

MATERIALS AND METHODS

Bacterial Strains

P. aeruginosa American Type Culture Collection strain PAO1 was used for most experiments. Other strains are described in Supplementary Tables 1 and 2. Bacteria were grown overnight in CA-MHB (20–25 mg/L Ca2+; 10–12.5 mg/L Mg2+) at 37°C with constant shaking (130 rpm) and under aerobic conditions, prior to use in experiments.

MIC Determination, Time- and Concentration-Kill Studies, and Assessment of Synergy

MICs were measured by microdilution [5] in CA-MHB or another medium, as indicated in the Results. Phe-Arg-β-naphthylamide (PaβN) was used as inhibitor of active efflux [13]. Time-kill and concentration-kill studies were performed as described previously [14]. Synergy was tested using the microtiter checkerboard method [15], with data used to calculate the fractional inhibitory concentration parameter (ΣFIC; values ≤0.5 are considered synergistic).

Uptake of Clarithromycin

Overnight cultures of PAO1 were diluted to 109 colony-forming units (CFU)/mL into CA-MHB or Roswell Park Memorial Institute (RPMI) 1640 medium and grown for 4 or 8 hours in the same medium with 10 mg/L of [14C]-clarithromycin. Bacteria were collected by centrifugation (1000g for 7 minutes at 4°C), washed 3 times with ice-cold phosphate-buffered saline, and lysed by 2 cycles of freezing (at −80°C) and thawing. Radioactivity counts (Tri-carb 2800TR, PerkinElmer, Waltham, MA) were normalized by reference to samples protein content (Bio-Rad Protein Assay Kit, Bio-Rad Laboratories, Hercules, CA).

Protein Synthesis

[3H]-leucine incorporation in proteins was evaluated in PAO1 incubated for 4 hours in CA-MHB or RPMI 1640 medium in the presence of increasing concentrations of azithromycin, with 2 µCi/mL [3H]-leucine added during the last 2 hours [16].

Expression of mexA, mexC, mexE, mexX, and oprM

Overnight cultures were resuspended at an optical density (620 nm) of 0.2 in 20 mL of CA-MHB or RPMI 1640 medium (with or without 1 mg/L azithromycin), grown at 37°C for 4 or 8 hours, harvested by centrifugation (10 000g for 10min), frozen, and kept at −80°C. After total RNA extraction and reverse transcription [17], mexC and mexE were detected by polymerase chain reaction (PCR) on complementary DNA (cDNA) [17], and mexA, mexX, and oprM were quantified by real-time PCR in 25-µL reaction mixtures containing 12.5 µL of iQ SYBR Green Supermix (2x), 400 nM of forward and reverse primers, and 5 µL of cDNA in RNase/DNase-free water, using an iQ cycler (Bio-Rad Laboratories). mexA and mexX were amplified using P. aeruginosa MexQ-TesT (CORIS BioConcept, Gembloux, Belgium), and oprM was amplified with previously described primers, using rpsl as housekeeping gene [18].

Assessment of Outer-Membrane Permeability

Overnight cultures of PAO1 were resuspended at a density of 109 CFU/mL into CA-MHB, RPMI 1640 medium (without phenol red), or mouse bronchoalveolar lavage (BAL) fluid. 1-N-phenylnaphthylamine (NPN; validated nonpermanent tracer that becomes fluorescent when partitioned in the lipid bilayer of the inner membrane [19]) and nitrocefin (chromogenic substrate of β–lactamases [2]) were used in parallel. NPN assay was performed as previously described [20], except that the NPN concentration was 25 μM and bacteria were resuspended in the medium under study. Nitrocefin assay was performed as previously described [21], after 2-hour induction of β–lactamase expression by exposure to cefoxitin (50 mg/L; [22]). Full outer-membrane permeabilization was achieved by addition of 10 mM of ethylenediaminetetraacetic acid (EDTA) in 10 mM Tris buffer (pH 8.0), which gave a signal similar to that for bacteria lysed by sonication [23].

Source of Products

The following antibiotics were obtained as microbiological standards (potencies are specified in parentheses): clarithromycin (100%) and azithromycin (100%), from Teva, Plantex, Israel; telithromycin (99.3%), from Sanofi-Aventis, Romainville, France; and solithromycin (100%), from Cempra Pharmaceuticals, Chapel Hill, North Carolina. Erythromycin (91.6%) and clindamycin (89.2%) were purchased from Sigma-Aldrich, St. Louis, Missouri. [6-O-methyl-14C]-clarithromycin (54.2 mCi/mmol) was provided by Moravek Biochemicals (Brea, CA), and l-[4,5-3H]leucine (69 Ci/mmol), by Amersham (Buckinghamshire, United Kingdom). EDTA and PaβN were purchased from Sigma-Aldrich, and minimum essential medium (MEM; reference 31095), RPMI 1640 medium (reference 21875), RPMI 1640 medium without phenol red (reference 11835), RPMI 1640 medium without NaHCO3 (reference 51800-035), MEM–nonessential amino acids (MEM-NEAA; reference 11140), and fetal bovine serum (reference 10270) were obtained from Invitrogen (Paisley, Scotland, United Kingdom). Human serum (reference 14-490E) was purchased from Lonza Braine SA (Braine-l'Alleud, Belgium). Broth (CA-MHB [reference 212322], brain heart infusion broth [reference 211059], Luria Bertani broth [reference 244620], and tryptic soy broth [reference 211825]) were purchased from BD Bioscience, Franklin Lakes, New Jersey. Mouse BAL fluid was kindly provided by Dr H. Tiesset (Inserm U 1019–CNRS UMR8204 INSERM, Lille, France).

RESULTS

Influence of Culture Medium on the MIC of Azithromycin and Other Macrolides

Figure 1A shows that the MIC of azithromycin against PAO1 was 256 mg/L in CA-MHB and ≥64 mg/L in other broths. In contrast, its MIC was only 2 mg/L when measured in RPMI 1640 medium or MEM (alone or supplemented with 10% fetal calf serum), 2 media commonly used for culturing eukaryotic cells. Figure 1B shows that mixing CA-MHB and RPMI 1640 medium supplemented with 10% fetal calf serum in inversely related proportions resulted in MICs of almost exactly the value anticipated from their respective concentrations on the basis of the previous experiment. Constituents of RPMI 1640 medium added individually to CA-MHB did not modify the azithromycin MIC (Supplementary Table 1). All of these experiments were repeated with clarithromycin, with essentially similar results (data not shown).

Figure 1.

Influence of medium on the minimum inhibitory concentration (MIC) of azithromycin against Pseudomonas aeruginosa PAO1. A, MICs were measured in cation-adjusted Muller-Hinton broth (CA-MHB), Luria Bertani broth, tryptic soy broth, and brain heart infusion broth or in eukaryotic cell culture media without (Roswell Park Memorial Institute 1640 medium [RPMI] and minimum essential medium [MEM]) or with (RPMI-S and MEM-S) 10% of fetal calf serum (FCS). B, MICs were determined in CA-MHB mixed with increasing proportions of RPMI-S. C, Influence of FCS (solid line) or human serum (dotted line) on azithromycin MIC against P. aeruginosa PAO1. MICs were determined in CA-MHB (open symbols) or RPMI (closed symbols) complemented with the indicated amounts of serum. D and E, Influence of pH on MIC measured in different media buffered using 10 mM NaH2PO4/Na2HPO4. D, Buffered CA-MHB (CA-MHBb), buffered RPMI-1640 with no bicarbonate supplemented by 10% of fetal calf serum (RPMIb-S), or a 50:50 buffered mixture of these media (CA-MHBb:RPMIb-S [50:50]). E, Buffered CA-MHB or buffered RPMI with no bicarbonate supplemented by 75% FCS (CA-MHBb + FCS [75%] and RPMI+ FCS [75%]). The arrows point to the pH value measured in nonbuffered CA-MHB (dotted arrow) or RPMI (plain arrow). Abbreviations: BHI, brain heart infusion broth; CA-MHB, cation-adjusted MHB; FCS, fetal calf serum; HS, human serum; LB, Luria Bertani broth; MEM, minimum essential medium; MEM-S, MEM with 10% FCS; MIC, minimum inhibitory concentration; MHB, Muller-Hinton broth; RPMI, Roswell Park Memorial Institute 1640 medium; RPMI-S, RPMI with 10% FCS; TS, tryptic soy broth.

Using CA-MHB and RPMI 1640 medium, we extended our observations to erythromycin and ketolides (telithromycin and solithromycin) and to other gram-negative bacteria, again with similar results (Supplementary Table 2). In contrast, no influence of media on the MIC of clindamycin (another inhibitor of protein synthesis binding to the 50S ribosomal subunit) was seen (Supplementary Table 2). Likewise, no decrease in MICs of β–lactams, fluoroquinolones, aminoglycosides, and colistin was observed when PAO1 was incubated in RPMI 1640 medium (data not shown). Last, no influence of the medium on azithromycin MIC for S. aureus ATCC25923 was seen (0.5 mg/L in CA-MHB or RPMI 1640 medium).

MIC of Azithromycin in CA-MHB Supplemented With Serum and in Mouse BAL

To check whether the increased susceptibility of P. aeruginosa to azithromycin was specific to media used to cultivate eukaryotic cells, we used CA-MHB supplemented with fetal calf serum or human serum and mouse BAL fluid. With serum, the MIC progressively decreased in proportion to the ratio of serum to broth (Figure 1C; MICs could not be measured in 100% serum [no bacterial growth]). In contrast, serum did not affect the MIC in RPMI 1640 medium. In BAL fluid, the azithromycin MIC was 16 mg/L. Comparable results were obtained with clarithromycin (data not shown).

Influence of pH

RPMI 1640 medium contains NaHCO3, which causes a slow increase in pH, from approximately 7.4 to approximately 8.3, within 24 hours when incubation is performed in 100% air atmosphere, as done here. Figure 1D, however, shows that the azithromycin MIC remained elevated (32 mg/L) in CA-MHB at pH 8.3 (the pH of nonbuffered CA-MHB at 24 hours was 7.9). An MIC of 32 mg/L was already reached at pH 7.5 in RPMI 1640 medium. Intermediate MICs were observed for 50:50 mixtures of both media over the whole pH range. In the presence of 75% serum (Figure 1E), an MIC of 4 mg/L was observed in both CA-MHB and RPMI 1640 medium at pH 7.5, ruling out a simple pH effect as the cause of the decrease in MIC in biologically relevant media.

Influence of Culture Medium on Time-Kill Curves

To test whether the increased susceptibility of P. aeruginosa to azithromycin in RPMI 1640 medium was a fast-occurring phenomenon, bacteria were exposed to azithromycin first in CA-MHB or in RPMI 1640 medium for 4 hours, using a concentration (128 mg/L) that was subinhibitory in the former medium but far above the MIC in the second, and were then transferred to the other medium for the next 20 hours. As controls, we used bacteria exposed to the same concentration of azithromycin for 24 hours without medium change and bacteria unexposed to azithromycin, with or without medium change. Figure 2 shows that bacteria exposed to azithromycin in CA-MHB for the first 4 hours remained unaffected but were quickly killed after transfer to RPMI 1640 medium. Conversely, bacteria exposed to azithromycin in RPMI 1640 medium for the first 4 hours suffered a loss of about 1.5 log10 cfu but, when transferred to CA-MHB, started growing essentially like the control. No difference in control inoculum was noted between the 2 media at that time point, demonstrating that differences in activity were not related to variations in bacterial growth. Experiments with no medium change showed that bacteria grew slightly slower in RPMI 1640 medium than in CA-MHB and that azithromycin was poorly effective over time in CA-MHB but strongly bactericidal in a time-dependent fashion in RPMI 1640 medium (experiments made at 16 mg/L yielded similar results).

Figure 2.

Activity of azithromycin (128 mg/L) against Pseudomonas aeruginosa PAO1 over time during successive incubation in cation-adjusted Muller-Hinton broth (CA-MHB; 4 hours) followed by Roswell Park Memorial Institute 1640 medium (RPMI; 20 hours; top left) or in RPMI (4 hours) followed by CA-MHB (20 hours; bottom left) in comparison with continuous incubation either in RPMI (top right) or CA-MHB (bottom right). The ordinate shows the change in colony-forming units (cfu) as compared to the initial inoculum (106 cfu/mL). All values are means ± standard deviation (SD; n = 3; when not visible, the SD bars are smaller than the size of the symbols). The horizontal dotted line corresponds to an apparent static effect, and the vertical dotted line in the left panel corresponds to the time at which bacteria were transferred from one medium to the other. Abbreviations: CA-MHB, cation-adjusted Muller-Hinton broth; RPMI, Roswell Park Memorial Institute 1640 medium.

Influence of Culture Medium on the Accumulation of Clarithromycin

The influence of medium on macrolide accumulation in P. aeruginosa was tested using [14C]-labeled clarithromycin (which was the only radiolabeled macrolide available to us). Clarithromycin accumulation measured after 4 and 8 hours of contact was 1.6- and 2.2-fold higher in bacteria incubated in RPMI 1640 medium than in those incubated in CA-MHB.

Influence of Culture Medium on the Inhibition of Protein Synthesis by Azithromycin

Figure 3 shows that [3H]-leucine incorporation in newly synthesized proteins was inhibited by lower concentrations of azithromycin with PAO1 incubated in RPMI 1640 medium versus CA-MHB, indicating a more effective inhibition of protein synthesis in the first medium.

Figure 3.

Incorporation of [3H]-leucine in proteins of PAO1 incubated for 4 hours in the presence of increasing concentration of azithromycin in cation-adjusted Muller-Hinton broth (CA-MHB; open symbols) or in Roswell Park Memorial Institute 1640 medium (RPMI; closed symbols); 2 µCi/mL [3H]-leucine was added during the 2 last hours. The pH of the media at the end of the experiment was 7.4 (for CA-MHB) and 7.7 (for RPMI). Data are expressed as the percentage of the value measured in the same medium in the absence of antibiotic and are the mean of triplicates ± standard error of the mean from 2 independent experiments. P < .001, by 2-way analysis of variance, with respect to either medium effect or concentration effect. Abbreviations: CA-MHB, cation-adjusted Muller-Hinton broth; RPMI, Roswell Park Memorial Institute 1640 medium.

Influence of oprM Expression and of the Addition of PaβN on MICs of Macrolides and Ketolides

The MICs of azithromycin and other macrolides and ketolides was measured against a panel of 42 strains with distinct expression of the main efflux systems in P. aeruginosa (MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM; Supplementary Table 3). Strains with a deletion in oprM all showed a low MIC in CA-MHB (illustrated for azithromycin in Figure 4A). In contrast, strains with deletions in other genes all had a high MIC for azithromycin (and for other macrolides and ketolides) in CA-MHB. Of interest, some of the strains with the oprM deletion still showed MICs that were 1 or 2 dilutions lower in RPMI 1640 medium than those measured for strains with no OprM deletion (Figure 4A and Supplementary Table 3). This indicates that OprM-dependent efflux could still operate but at a low level in RPMI 1640 medium (this was even more evident for other macrolides and ketolides; Supplementary Table 3). Last, addition of the broad-spectrum efflux inhibitor PaβN to PAO1 in CA-MHB reduced the MIC of azithromycin to 4 mg/L but had no effect on its MIC in RPMI 1640 medium (data not shown).

Figure 4.

A, Cumulative minimum inhibitory concentration (MIC) of azithromycin (AZM) against 42 strains of Pseudomonas aeruginosa with different levels of expression of the genes encoding the main efflux systems (MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM). Strains have been stratified for positive (squares; solid lines) or negative (circles; dotted lines) expression of oprM and for results obtained in cation-adjusted Muller-Hinton broth (CA-MHB; open symbols) or in Roswell Park Memorial Institute 1640 medium (RPMI; closed symbols). Individual MICs and strain phenotypes are presented in Supplementary Table 3. B, expression of oprM (relative to that measured after 4 hours in CA-MHB in the absence of AZM) in bacteria grown in CA-MHB (open bars) or in RPMI (closed bars) in the absence (left) or presence (right) of 1 mg/L AZM. The pH of the media at the end of the experiment was 7.4 (for CA-MHB) and 7.7 (for RPMI). *P < .05, by the t test, comparing expression in the 2 media at the same time point. Abbreviations: CA-MHB, cation-adjusted Muller-Hinton broth; MIC, minimum inhibitory concentration; RPMI, Roswell Park Memorial Institute 1640 medium.

Impairment of oprM Expression by Azithromycin in RPMI 1640 Medium

The expression of oprM in PAO1 was measured after 4 or 8 hours of incubation in CA-MHB or in RPMI 1640 medium (Figure 4B). There was no difference in oprM expression for bacteria cultivated in the absence of antibiotic. However, the addition of a subinhibitory concentration of azithromycin (1 mg/L) caused a marked decrease of oprM expression in bacteria grown in RPMI 1640 medium but no change in those grown in CA-MHB.

Influence of the Culture Medium on Outer-Membrane Permeability

Figure 5 shows that the permeability of PAO1 to NPN and nitrocefin was markedly increased in RPMI 1640 medium, reaching 90% and 60%, respectively, of the maximal value recorded in the presence of EDTA. NPN permeability was also increased in bacteria grown in mouse BAL. In an independent approach, we examined whether agents disrupting the outer membrane of P. aeruginosa would be synergistic with azithromycin in CA-MHB. This was the case for colistin [24], the ceragenin CSA-13 [25], and EDTA [26], with ΣFIC indices (± standard deviation) of 0.52 ± 0.03, 0.23 ± 0.04, and 0.07 ± 0.01, respectively. These combinations were indifferent in RPMI 1640 medium.

Figure 5.

Outer-membrane permeability of Pseudomonas aeruginosa PAO1 to 1-N-phenylnaphthylamine (NPN; 25 µM; left panel) or to nitrocefin (100 µM; right panel). Bacteria were incubated for 4 hours in cation-adjusted Muller-Hinton broth (CA-MHB; open bars), bronchoalveolar lavage fluid (BAL; grey bar), or Roswell Park Memorial Institute 1640 medium (RPMI; black bar). Data are expressed as a percentage of the maximal value recorded in the presence of 10 mM EDTA in 10 mM Tris buffer (pH 8) and are the mean ± standard deviation of 3 independent determinations. No significant difference was found when permeability to nitrocefin was measured in RPMI without NaHCO3 and buffered at pH 7.4 as compared to nonbuffered RPMI. P < .001, by analysis of variance and the Tukey post-hoc test, for comparisons of RPMI and CA-MHB for both NPN and nitrocefin and for comparison of BAL with CA-MHB for NPN. Abbreviations: BAL, bronchoalveolar lavage fluid; MHB, Muller-Hinton broth; NPN, 1-N-phenylnaphthylamine; RPMI, Roswell Park Memorial Institute 1640 medium.

DISCUSSION

This article shows that macrolides and ketolides but not any of the other antibiotics tested (ie, clindamycin and antipseudomonal drugs) have considerably lower MICs against P. aeruginosa when assayed in media used for culturing eukaryotic cells, broth supplemented with serum, or BAL fluid, compared with CA-MHB (recommended for in vitro susceptibility testing studies [5]) or other broths. Since antibiotic susceptibility is a key property to consider when assessing their clinical usefulness [27], our observations open potentially important perspectives concerning the clinical benefit of macrolides and ketolides for patients with pseudomonal infections.

New, unanticipated observations with the potential to modify current therapeutic approaches need critical examination concerning reproducibility, consistency and specificity, underlying mechanism, and scope of application.

Our studies yielded reproducible and consistent observations when comparing conventional microbiological media and media with a composition close to that of eukaryotic environments. They could be extended to a large array of clinical strains of P. aeruginosa, other gram-negative organisms, and macrolides and ketolides but not to other antibiotics or gram-positive bacteria. Taken globally, they show that the activity of macrolides and ketolides is impaired in broths as compared to media closer to the eukaryotic environment. The data shows that MICs in CA-MHB are not decreased by addition of individual constituents found in RPMI 1640 medium (making unlikely a mechanism based on simple drug complexation) and that a progressive replacement of CA-MHB by serum brings MICs to values close to those measured in RPMI 1640 medium, whereas serum does not affect MICs measured in RPMI 1640 medium. RPMI 1640 medium and serum effects are observed over a broad pH range, demonstrating that macrolide protonation state is not the main determinant in the increased activity observed in biological media but is rather another, independent mechanism that modulates macrolide activity. Inhibition of activity in CA-MHB requires direct contact and is transient, since it appears and/or is quickly lost when bacteria are transferred from CA-MHB to RPMI 1640 medium or vice versa, and is independent of bacterial growth rate.

Two nonmutually exclusive molecular mechanisms may account for these effects, namely, impairment of efflux of macrolides and increased outer-membrane permeability to these antibiotics.

Evidence for an active efflux in CA-MHB can be deduced from the facts that the efflux pump inhibitor PAβN brings MICs measured in CA–MHB to values close to those measured in RPMI 1640 medium and that disruption of oprM (encoding the outer-membrane protein working in conjunction with the 2 constitutively expressed multidrug efflux pumps, MexB and MexY [28]) drastically reduces MICs in CA-MHB. Erythromycin is a substrate for MexAB-OprM, MexCD-OprJ, and MexXY-OprM but not for MexEF-OprN in P. aeruginosa [29, 30], and MexAB-OprM and MexXY-OprM are involved in intrinsic resistance of P. aeruginosa to macrolides [30]. In line with these observations, we noted a significant reduction in the expression of oprM for bacteria incubated with a sub-MIC of azithromycin (1 mg/L) in RPMI 1640 medium. As OprM works in conjunction with the 2 constitutive transporters involved in macrolide efflux, reduction in its expression is anticipated to have important effects. Indeed, we showed an increased drug accumulation in bacteria incubated in RPMI 1640 medium versus CA-MHB (demonstrated for clarithromycin), together with an inhibition of protein synthesis upon exposure to lower antibiotic concentrations, as previously described [31]. The increase in clarithromycin bacterial accumulation may seem too modest to account for the change in MIC observed. Yet, similar values were observed when comparing MICs and accumulation of ciprofloxacin in P. aeruginosa expressing efflux systems at different levels [32]. However, the presence of azithromycin (presumably in bacteria) is necessary to induce downregulation of oprM. This implies that an additional mechanism must first ensure a larger initial penetration of the antibiotic in bacteria grown in eukaryotic media versus CA-MHB.

Evidence of an increased permeability of the outer membrane of P. aeruginosa when grown in RPMI 1640 medium or BAL fluid versus CA-MHB was documented by the increased accumulation of NPN and nitrocefin. While the magnitude of the effect depends on the size of the marker, it remains significant for a molecule with a molecular weight of 515 Da (nitrocefin), which is close to that of macrolides (around 740 Da). Indirect confirmation of the low outer-membrane permeability of P. aeruginosa in CA-MHB as compared to RPMI 1640 medium stems from the synergistic effect seen between membrane-destabilizing agents (colistin and CSA-13) with azithromycin in CA-MHB (but not or only to a minimal extent in RPMI 1640 medium).

Macrolides poorly diffuse across the outer membrane of most gram-negative bacteria [21]. Our experiments bring complementary pieces of evidence supporting the concept that high susceptibility of P. aeruginosa to macrolides in RPMI 1640 medium and other eukaryotic media as compared to broths is probably related to an increase in their accumulation within the bacteria, consecutive to an alteration of the outer-membrane integrity (mediated by the nature of the medium in contact with bacteria) combined with an impairment of their active efflux. Figure 6 presents a schematic view of these proposed mechanisms, which, notably, have been evidenced at concentrations (0.5–4 mg/L) relevant to those reached in the serum or tissues of patients receiving azithromycin at the registered dosage [33].

Figure 6.

Model depicting the proposed mechanisms contributing to the differences in susceptibility of Pseudomonas aeruginosa to macrolides (MLs) in cation-adjusted Muller-Hinton broth (CA-MHB; left) and in a culture medium of eukaryotic cells (Roswell Park Memorial Institute 1640 medium [RPMI]). In CA-MHB (the recommended medium to assess P. aeruginosa susceptibility to antibiotics, according to the Clinical and Laboratory Standards Institute), MLs show a high minimum inhibitory concentration because of a poor diffusibility through the outer membrane (depending on the protonation state of the macrolide) and because of active efflux by the constitutively expressed efflux systems MexAB-OprM and MexXY-OprM, which in combination ensures a low intrabacterial antibiotic concentration. In RPMI, the outer membrane becomes more permeable, which favors macrolide penetration within bacteria (1), allows them to impair, through a still undefined mechanism, the expression of oprM (2), and therefore reduces the activity of the efflux systems MexAB-OprM and MexXY-OprM (3). In combination, steps 1 and 4 allows for an increased intracellular accumulation of MLs and allows them to impair protein synthesis at lower extrabacterial concentrations (4) and, thereby, to exert true antibacterial activity. Abbreviations: MHB, Muller-Hinton broth; MIC, minimum inhibitory concentration; ML, macrolides; NPN, 1-N-phenylnaphthylamine; RPMI, Roswell Park Memorial Institute 1640 medium.

Pending further confirmatory studies, the present work opens new perspectives as to why macrolides may exert in vivo antibacterial properties against P. aeruginosa that would not be predicted on the basis of their reported activities in conventional antibiotic susceptibility testing systems. Our work, therefore, also suggests the need to actively develop more-pertinent in vitro models for susceptibility testing of antibiotics.

Notes

Acknowledgments. C. Misson, V. Mohymont, and K. Santos provided dedicated technical assistance. We thank Dr H. Rodriguez (Service de microbiologie, Hopital Saint Luc, Brussels, Belgium), Dr K. Jeannot (Laboratoire de Bactériologie, Hôpital Jean Minjoz, Besançon, France), and Drs D. De Vos and J. P. Pirnay (Laboratory for Molecular and Cellular Technology, Burn Centre, Queen Astrid Military Hospital, Brussels, Belgium), for the kind gift of strains; and the manufacturers, for providing free samples of their antibiotics.

Financial support. This work was supported by the Belgian Fonds pour la Recherche Scientifique Médicale (grants 3.5.597.06, 3.4.583.08 F, and 3.4.639.09 F) and the BioWin program of the Région Wallonne (BioFiNa). J. B. is a postdoctoral fellow of the BioWin program of the Région Wallonne, Belgium, and F. V. B. is Maître de Recherches of the Belgian Fonds National de la Recherche Scientifique.

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1
Mesaros
N
Nordmann
P
Plesiat
P
, et al. 
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium
Clin Microbiol Infect
2007
, vol. 
13
 (pg. 
560
-
78
)
2
Angus
BL
Carey
AM
Caron
DA
Kropinski
AM
Hancock
RE
Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant
Antimicrob Agents Chemother
1982
, vol. 
21
 (pg. 
299
-
309
)
3
Poole
K
Srikumar
R
Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance
Curr Top Med Chem
2001
, vol. 
1
 (pg. 
59
-
71
)
4
Livermore
DM
Yang
YJ
Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa
J Infect Dis
1987
, vol. 
155
 (pg. 
775
-
82
)
5
Performance standards for antimicrobial susceptibility testing
2010
 
20th informational supplement (MS100-S20). Wayne, PA: Clinical and Laboratory Standard Institute
6
Cai
Y
Chai
D
Wang
R
Bai
N
Liang
BB
Liu
Y
Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review
J Antimicrob Chemother
2011
, vol. 
66
 (pg. 
968
-
78
)
7
Konstan
MW
VanDevanter
DR
Rasouliyan
L
, et al. 
Trends in the use of routine therapies in cystic fibrosis: 1995–2005
Pediatr Pulmonol
2010
, vol. 
45
 (pg. 
1167
-
72
)
8
Yousef
AA
Jaffe
A
The role of azithromycin in patients with cystic fibrosis
Paediatr Respir Rev
2010
, vol. 
11
 (pg. 
108
-
14
)
9
Labro
MT
Anti-inflammatory activity of macrolides: a new therapeutic potential?
J Antimicrob Chemother
1998
, vol. 
41
 
Suppl B
(pg. 
37
-
46
)
10
Nalca
Y
Jansch
L
Bredenbruch
F
Geffers
R
Buer
J
Haussler
S
Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach
Antimicrob Agents Chemother
2006
, vol. 
50
 (pg. 
1680
-
8
)
11
Imamura
Y
Higashiyama
Y
Tomono
K
, et al. 
Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane
Antimicrob Agents Chemother
2005
, vol. 
49
 (pg. 
1377
-
80
)
12
Nagata
T
Mukae
H
Kadota
J
, et al. 
Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model
Antimicrob Agents Chemother
2004
, vol. 
48
 (pg. 
2251
-
9
)
13
Lomovskaya
O
Warren
MS
Lee
A
, et al. 
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy
Antimicrob Agents Chemother
2001
, vol. 
45
 (pg. 
105
-
16
)
14
Seral
C
Van Bambeke
F
Tulkens
PM
Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages
Antimicrob Agents Chemother
2003
, vol. 
47
 (pg. 
2283
-
92
)
15
Kluge
RM
Standiford
HC
Tatem
B
, et al. 
Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa
Antimicrob Agents Chemother
1974
, vol. 
6
 (pg. 
442
-
6
)
16
Baussanne
I
Bussiere
A
Halder
S
, et al. 
Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives
J Med Chem
2010
, vol. 
53
 (pg. 
119
-
27
)
17
Mesaros
N
Glupczynski
Y
Avrain
L
Caceres
NE
Tulkens
PM
Van Bambeke
F
A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa
J Antimicrob Chemother
2007
, vol. 
59
 (pg. 
378
-
86
)
18
Wolter
DJ
Black
JA
Lister
PD
Hanson
ND
Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype
J Antimicrob Chemother
2009
, vol. 
64
 (pg. 
294
-
300
)
19
Helander
IM
Mattila-Sandholm
T
Fluorometric assessment of gram-negative bacterial permeabilization
J Appl Microbiol
2000
, vol. 
88
 (pg. 
213
-
9
)
20
Loh
B
Grant
C
Hancock
RE
Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa
Antimicrob Agents Chemother
1984
, vol. 
26
 (pg. 
546
-
51
)
21
Nikaido
H
The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access?
Drug Resist Updat
1998
, vol. 
1
 (pg. 
93
-
8
)
22
Hancock
RE
Raffle
VJ
Nicas
TI
Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa
Antimicrob Agents Chemother
1981
, vol. 
19
 (pg. 
777
-
85
)
23
Runyan
CM
Carmen
JC
Beckstead
BL
Nelson
JL
Robison
RA
Pitt
WG
Low-frequency ultrasound increases outer membrane permeability of Pseudomonas aeruginosa
J Gen Appl Microbiol
2006
, vol. 
52
 (pg. 
295
-
301
)
24
Nakajima
K
Kawamata
J
Studies on the mechanism of action of colistin. II. Alteration of permeability of Escherichia coli by colistin
Biken J
1965
, vol. 
8
 (pg. 
233
-
9
)
25
Savage
PB
Li
C
Taotafa
U
Ding
B
Guan
Q
Antibacterial properties of cationic steroid antibiotics
FEMS Microbiol Lett
2002
, vol. 
217
 (pg. 
1
-
7
)
26
Stinnett
JD
Gilleland
HE
Jr
Eagon
RG
Proteins released from cell envelopes of Pseudomonas aeruginosa on exposure to ethylenediaminetetraacetate: comparison with dimethylformamide-extractable proteins
J Bacteriol
1973
, vol. 
114
 (pg. 
399
-
407
)
27
Pillai
SK
Eliopoulos
GM
Moellering
RC
Jr
Mandell
GL
Bennet
JE
Dolin
R
Principles of anti-infective therapy
Principles and practice of infectious diseases
2010
Philadelphia, PA; Elsevier
(pg. 
267
-
78
)
28
Schweizer
HP
Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions
Genet Mol Res
2003
, vol. 
2
 (pg. 
48
-
62
)
29
Maseda
H
Yoneyama
H
Nakae
T
Assignment of the substrate-selective subunits of the MexEF-OprN multidrug efflux pump of Pseudomonas aeruginosa
Antimicrob Agents Chemother
2000
, vol. 
44
 (pg. 
658
-
64
)
30
Masuda
N
Sakagawa
E
Ohya
S
Gotoh
N
Tsujimoto
H
Nishino
T
Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa
Antimicrob Agents Chemother
2000
, vol. 
44
 (pg. 
3322
-
7
)
31
Tateda
K
Ishii
Y
Matsumoto
T
Kobayashi
T
Miyazaki
S
Yamaguchi
K
Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response
J Infect Chemother
2000
, vol. 
6
 (pg. 
1
-
7
)
32
Cai
H
Rose
K
Liang
LH
Dunham
S
Stover
C
Development of a liquid chromatography/mass spectrometry-based drug accumulation assay in Pseudomonas aeruginosa
Anal Biochem
2009
, vol. 
385
 (pg. 
321
-
5
)
33
Foulds
G
Shepard
RM
Johnson
RB
The pharmacokinetics of azithromycin in human serum and tissues
J Antimicrob Chemother
1990
, vol. 
25
 
Suppl A
(pg. 
73
-
82
)

Supplementary data

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.